: iStockAnalyst.com Symbols Feed

Stock Futures Drop, Improve to Trade Mixed After Surprise Slide in Durable Goods Orders - Airlines Upgraded, RIMM Warns

Fri, 25 Sep 2009 13:10:46 GMT

Stock futures turned lower, then improved to trade narrowly mixed, following the release of unexpectedly weak durable goods orders data. Futures were just positive ahead of the data. U.S. stocks fell in back-to-back sessions over the last two days, with averages depressed Thursday following an unexpected drop for home resales after several months of improvement.[More...]

Looking For Solid, Growing Companies In A Recession

Mon, 29 Jun 2009 12:33:44 GMT

In dedication to my recent posts on value investing vs. trading strategies, I decided to focus this week’s screen to the market’s favorite word: growth. Specifically, the criteria used was positive revenue growth for the next fiscal year. Of course, this does not translate to earnings growth but management teams should have figured out there’s (...)[More...]

Biotech Industry Overview

Mon, 01 Jun 2009 14:38:59 GMT

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]

FDA, Clinical Trial Calendar Updates: Acorda(Nasdaq: ACOR), Alkermes(Nasdaq: ALKS), GTx(Nasdaq: GTXI)

Thu, 23 Apr 2009 16:53:00 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA (...)[More...]

Biotech Industry - Industry Outlook

Thu, 16 Apr 2009 20:54:01 GMT

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]

Alkermes Downgraded to Sell

Mon, 09 Feb 2009 17:21:00 GMT

Highlighted are the following stocks: Alkermes (ALKS), Cephalon (CEPH) and Eli Lilly (LLY). Alkermes Enters Into Uncharted Territory We downgrade Alkermes (ALKS) shares from Hold to Sell based on the financial performance in fiscal 3rd quarter of 2009 ended December 31, 2008 and the bleak outlook of the company in the next few[More...]

Pre Market Stock News Brief

Mon, 01 Dec 2008 14:00:00 GMT

U.S. PRE-MARKET INDICATORS -Dow Industrial futures down 170 points -S&P 500 futures down 24 points. -Nasdaq futures down 27 points. -Nasdaq-100 Pre-Market Indicator down 12.28 to 1173.47. GLOBAL SENTIMENT Nikkei down 1.4% Hang Seng up 1.6% FTSE down 2.9% PRE-MARKET SECTOR WATCH (-) Large cap tech: mostly lower (-) Chip stocks: lower (-,+) Small cap stocks: mixed (-,+) Drug stocks: mixed (-) Software stocks: lower (-) Internet stocks: lower (-) Financial[More...]

Bookkeeping: Beginning Amylin Pharmaceuticals (AMLN)

Wed, 20 Aug 2008 17:21:00 GMT

I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals (AMLN). This is one of the few biotechs I know pretty well, and have follow[More...]

Analyst Comments: Teekay, Advanced Micro, JC Penney, Zumiez, MarkWest Energy, UBS AG, Alkermes, Ev3 Inc

Thu, 14 Aug 2008 18:55:00 GMT

Despite a challenging fiscal third quarter in which profit and revenue declined from the previous year, shares of Applied Materials (AMAT) are up more than 5% Wednesday afternoon.[More...]

Few Thoughts and a Look at the Earnings in the Coming Week

Mon, 28 Jul 2008 05:15:00 GMT

WITH RESPECT TO THE US’ GDP GROWTH, THE NATIONAL BUREAU OF ECONOMIC RESEARCH SEES A SIGNIFICANT DECLINE IN ECONOMIC ACTITIVY SPREAD ACROSS THE ECONOMY, WHICH WILL LAST MORE THAN A FEW MONTHS - WSJ - According to Robert Hall, economist at Stanford University, US economic data that has been reported provide (...)[More...]

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on ALV, CLS, VIT, TKC, CRK and ALKS

Tue, 13 Oct 2009 12:07:00 GMT

RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment.
Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.
We have recently begun in-depth analysis of the following equities & their respective sectors:

[More...]

Alkermes Reports First Quarter Fiscal 2010 Financial Results

Thu, 06 Aug 2009 19:59:00 GMT

Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its first quarter of fiscal 2010, which ended on June 30, 2009.[More...]

Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010

Thu, 30 Jul 2009 20:00:00 GMT

Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, August 6, 2009, to discuss the company’s financial results for the first quarter of fiscal 2010. Management will review the quarter and provide an update on the company.[More...]

Alkermes’ Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

Wed, 29 Jul 2009 19:59:00 GMT

Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by BMO Capital Markets on Wednesday, August 5, 2009, at 1:15 p.m. ET from the Millennium Broadway Hotel in New York City. The presentation may be accessed under the investor relations tab at www.alkermes.com. The presentation will be archived for 14 days.[More...]

BenchmarkJournal.Com Free Analyst Review for ITUB, APWR, CHRS, FMBI, ALKS and HANS

Wed, 22 Jul 2009 14:19:00 GMT

Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.
Today we began research on Itau Unibanco Holding SA (NASDAQ: ITUB), A-Power Energy Generation Systems Ltd. (NASDAQ: APWR), Charming Shoppes Inc. (NASDAQ: CHRS), First Midwest Bancorp Inc. (NASDAQ: FMBI), Alkermes Inc. (NASDAQ: ALKS) and Hansen Natural Corporation (NASDAQ: HANS).
To view our research, sign up now and get started with your complimentary subscription.

[More...]

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

Mon, 20 Jul 2009 20:10:00 GMT

Amylin Pharmaceuticals, Inc., , Eli Lilly and Company and Alkermes, Inc. today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus) . Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments. In addition, although patients treated with exenatide once weekly experienced a greater reduction in blood glucose than those treated with Lantus, they also reported significantly fewer episodes of confirmed hypoglycemia.These intent-to-treat results were from DURATION-3, the third in a series of studies designed to test the superiority of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes medications. This 26-week open-label clinical study compared exenatide once weekly to once-daily doses of Lantus in 467 patients with type 2 diabetes taking stable doses of metformin alone or in combination with a sulfonylurea. Exenatide once weekly was administered once a week in a fixed dose while Lantus was administered daily in a variable dose determined by patient blood sugar levels.'Exenatide once weekly outperformed Lantus in this superiority study by meeting its primary endpoint,' stated Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. 'Both treatment arms started with a baseline A1C of 8.3 percent and exenatide once weekly provided statistically significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of hypoglycemia.'More than 90 percent of patients completed the study. During the 26-week treatment period, the most frequently reported adverse events were upper respiratory infection, including nasopharyngitis, in both treatment arms, as well as gastrointestinal events, including nausea, in the exenatide once weekly treatment group. Patients treated with exenatide once weekly experienced less confirmed hypoglycemia: the incidence of hypoglycemia was 4 percent with exenatide once weekly versus 19 percent with Lantus for patients on metformin background therapy, and 20 percent with exenatide once weekly versus 44 percent with Lantus for patients on metformin and a sulfonylurea background therapy, differences that are statistically significant in both treatment groups. Study DesignThe 26-week open-label, superiority study included 467 subjects with type 2 diabetes who were not achieving adequate glucose control using metformin therapy alone or in combination with a sulfonylurea. Subjects were randomized to receive exenatide once weekly 2 milligrams by subcutaneous injection weekly or insulin glargine injections administered daily in a variable dose determined by patient blood sugar levels. There was no lead-in or wash-out period. The primary endpoint was reduction in A1C; secondary endpoints included change in body weight along with other parameters of glucose control, cardiovascular health, hypoglycemia and patient-reported outcomes. Subjects in both treatment groups are continuing in an open-ended extension study.The companies plan to present the full data set at a major medical meeting and submit the data for publication.About Diabetes Diabetes affects more than 23 million people in the U.S. and an estimated 246 million adults worldwide. Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the U.S. and results in approximately $174 billion per year in direct and indirect medical expenses. According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen. In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese. Data indicate that weight loss supports patients in their efforts to achieve and sustain glycemic control.About Amylin, Lilly and Alkermes Amylin, Lilly and Alkermes are working together to develop exenatide once weekly, a subcutaneous injection of exenatide for the treatment of type 2 diabetes based on Alkermes' proprietary technology for long-acting medications. Exenatide once weekly is not currently approved by any regulatory agencies. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio. This press release contains forward-looking statements about Amylin, Lilly and Alkermes and the investigational drug, exenatide once weekly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that exenatide once weekly may be affected by unexpected new data; safety and technical issues; clinical trials, including the clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; the DURATION-3 superiority study results potentially not being predictive of real world use including results relative to other diabetes medications; pre-clinical trials not predicting future results; label expansion requests or New Drug Application filings, not being submitted in a timely manner; regulatory approval, including approval for exenatide once weekly, being delayed or not received; or manufacturing and supply issues. The potential for exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.P-LLY "All About Diabetes." American Diabetes Association. Available at: http://www.diabetes.org/about-diabetes.jsp. Accessed July 13, 2009. The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A. Accessed July 13, 2009. "Direct and Indirect Costs of Diabetes in the United States." American Diabetes Association. Available at: http://www.diabetes.org/diabetes-statistics/cost-of-diabetes-in-us.jsp. Accessed July 13, 2009. Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes." JAMA: 291, January 21, 2004. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737-47. Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl 1:S61-78. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22:331-9.[More...]

Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus® in Head-to-Head DURATION-3 Study

Mon, 20 Jul 2009 20:02:00 GMT

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.[More...]

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

Tue, 07 Jul 2009 20:00:00 GMT

Amylin Pharmaceuticals, Inc., , Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration .[More...]

Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare Conference

Wed, 10 Jun 2009 19:58:00 GMT

Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by Jefferies & Company on Wednesday, June 17, 2009, at 2:00 p.m. ET from New York City. The presentation may be accessed under the investor relations tab at www.alkermes.com. The presentation will be archived for 14 days.[More...]

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

Sun, 07 Jun 2009 13:11:00 GMT

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq: ALKS) today announced long-term, interim results from the DURATION-1 study that showed sustained glucose control with weight loss, as well as improvements in systolic blood pressure and triglycerides, through two years of treatment with exenatide once weekly, an investigational therapy for type 2 diabetes. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S. Food and Drug Administration.[More...]